Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment

Issue Date: February 24, 2023
Issued by: Center for Biologics Evaluation and Research
Topic(s): Clinical – Medical
Status: Draft

Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment

This guidance is intended to provide recommendations to sponsors regarding eligibility criteria, trial design considerations, and efficacy endpoints to enhance clinical trial data quality and to foster greater efficiency in development programs for drugs for the treatment of neovascular age-related macular degeneration.2, 3

Download the Guidance Document

webmaster2026-08-05T18:56:53+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.